Association between polymorphism gene ABCB1, encodes glycoprotein P, and efficacy and safety profile of haloperidol in patients with alcohol addiction

• Main Authors: M S Zastrozhin, K A Rizhikova, K B Mirzaev, Jh A Sozaeva, E A Grishina, D A Sychev, L M Savchenko, Yu Sh Gushina, S R Pahomov
• Format: Article
• Language: English
• Published: Peoples’ Friendship University of Russia (RUDN University) 2017-12-01
• Series: RUDN Journal of Medicine
• Subjects: галоперидол; полиморфизм; гликопротеин P; нежелательные лекарственные реакции; патологическое влечение к алкоголю
• Online Access: http://journals.rudn.ru/medicine/article/view/15225
• ISSN: 2313-0245; 2313-0261

Haloperidol is used in the practice of drug for relief of updating drives in patients suffering from a pathological attraction to alcohol, but the empirical selection of its dosage often leads to the development of patient adverse drug reactions. Synthesis of glycoprotein P, involved in the excretion of various xenobiotics including haloperidol encoded ABCB1 gene having a high level of polymorphism. Various ABCB1 allelic variations are associated with varying degrees of activity of glycoprotein P. Polymorphism 3435C>T is the functional polymorphism, which makes the activity of glycoprotein P slowly, that’s why its increase the level of concentration of xenobiotics (substrates of glycoprotein P) in blood-plasma and increase the risk of adverse drug reactions. Efficacy and safety of treatment with haloperidol was determined by international psychometric scales and scales for measure of extra pyramidal adverse drug reactions. ABCB1 genotyping was performed by polymerase chain reaction in real time (Real-time PCR) using allele-specific hybridization. According to the survey were identified statistically significant patterns between ABCB1 polymorphism and the efficacy and safety profile of haloperidol.